Related Experiment Video
Updated: Aug 15, 2025
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
6.4K
Acquired Factor XIII Deficiency in Patients with Multiple Trauma
Michael Hetz1, Tareq Juratli2, Oliver Tiebel3
1Department of Operative Medicine (DOPM), Clinic and Polyclinic for Orthopedics, Trauma Surgery and Plastic Surgery, University Hospital Leipzig AöR, Liebigstr. 20, 04103 Leipzig, Germany.
Injury
|December 28, 2022
Summary
Trauma-associated fibrin stabilizing factor (FXIII) deficiency is common and worsens in the first week post-injury. FXIII activity can predict outcomes in severe traumatic brain injury patients and improves clot stability.
Area of Science:
- Coagulation and Hemostasis
- Trauma Medicine
- Biochemistry
Background:
- Fibrin stabilizing factor (FXIII) is vital for hemostasis, tissue repair, and immune function.
- FXIII deficiency post-trauma can impede wound healing and cause coagulation disorders.
- Understanding FXIII's role in trauma is critical for patient management.
Purpose of the Study:
- To determine the prevalence of acquired FXIII deficiency in trauma patients.
- To analyze the time-course changes of coagulation parameters relative to FXIII activity.
- To investigate the prognostic value of FXIII activity in severe traumatic brain injury (sTBI).
Main Methods:
- Prospective and retrospective analysis of three trauma cohorts (n=990).
- Measurement of FXIII activity and routine coagulation parameters.
- In-vitro FXIII administration and rotational thromboelastometry (ROTEM) in a polytrauma cohort.
- Correlation of FXIII activity with clinical outcomes in sTBI patients using the modified Rankin Scale (mRS).
Main Results:
- 12.4% of trauma patients exhibited FXIII activity <70%.
- FXIII activity decreased significantly in the first 7 days post-trauma (85% to 58%).
- In-vitro FXIII improved clot firmness and reduced lysis; FXIII activity differentiated sTBI outcomes.
Conclusions:
- Trauma-associated FXIII deficiency is prevalent and exacerbates during early surgical care.
- FXIII administration demonstrates significant clot-stabilizing effects.
- FXIII activity serves as a potential prognostic biomarker for sTBI patients.
Related Concept Videos
01:20Extrinsic and Intrinsic Pathways of Hemostasis
8.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.7K
01:29Venous Thrombosis III: Interprofessional Care
16
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
16
01:24Disorders of Hemostasis
1.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
826
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
826
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Venous Thrombosis IV: Nursing Management
19
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
19